Insmed Incorporated (NASDAQ:INSM) Stock Holdings Trimmed by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB lowered its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 52.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,500 shares of the biopharmaceutical company's stock after selling 68,013 shares during the period. Rhenman & Partners Asset Management AB's holdings in Insmed were worth $4,246,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Insmed by 6.3% in the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after purchasing an additional 1,075,796 shares during the last quarter. Geode Capital Management LLC grew its stake in Insmed by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company's stock valued at $282,243,000 after acquiring an additional 273,759 shares during the last quarter. Artisan Partners Limited Partnership raised its position in Insmed by 8.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,126,339 shares of the biopharmaceutical company's stock worth $215,842,000 after acquiring an additional 242,242 shares during the last quarter. William Blair Investment Management LLC lifted its holdings in shares of Insmed by 0.5% in the fourth quarter. William Blair Investment Management LLC now owns 2,433,443 shares of the biopharmaceutical company's stock valued at $168,005,000 after purchasing an additional 12,535 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its position in shares of Insmed by 5.2% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,959,718 shares of the biopharmaceutical company's stock valued at $135,299,000 after purchasing an additional 96,377 shares during the last quarter.

Insider Activity

In other Insmed news, CEO William Lewis sold 2,978 shares of the company's stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.36, for a total value of $188,686.08. Following the transaction, the chief executive officer now directly owns 392,589 shares of the company's stock, valued at $24,874,439.04. This represents a 0.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the sale, the insider now directly owns 97,083 shares of the company's stock, valued at $7,766,640. The trade was a 48.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 514,731 shares of company stock worth $40,530,912 over the last 90 days. Company insiders own 4.60% of the company's stock.

Insmed Trading Down 6.9 %

Shares of Insmed stock traded down $4.63 during trading hours on Thursday, hitting $62.92. The company's stock had a trading volume of 887,671 shares, compared to its average volume of 2,259,846. The business has a fifty day moving average of $76.71 and a 200 day moving average of $73.73. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $11.39 billion, a PE ratio of -11.25 and a beta of 1.07.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The company had revenue of $104.44 million during the quarter, compared to analysts' expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. As a group, equities analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Analysts Set New Price Targets

INSM has been the subject of several research reports. Royal Bank of Canada restated an "outperform" rating and set a $100.00 price objective on shares of Insmed in a research report on Wednesday, March 19th. UBS Group upped their price objective on shares of Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Stifel Nicolaus lowered their target price on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research note on Friday, February 21st. HC Wainwright reissued a "buy" rating and set a $90.00 price target on shares of Insmed in a research note on Friday, February 21st. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Insmed has a consensus rating of "Moderate Buy" and a consensus price target of $94.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.